share_log

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $20

Benzinga ·  Oct 10 23:33  · Ratings

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $32 to $20.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment